Fundraising FoxHealthCap — 2020 Investments
4 investments dated 2020 · listed companies and verified rows first · show all
Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).
BiotechHealthtechSouth San Francisco, US
Samir Gharib(Executive Officer)inRICHARD KING(Executive Officer, Director)inJavier Szwarcberg(Chief Executive Officer)in
BoardSimpson Camilla(Director)Tiba Aynechi(Director)inBali Muralidhar(Director)in
Board seatJonas Hansson· per SEC Form D
Co-investorsAisling CapitalRiverVest Venture PartnersAbingworthNorwest Venture PartnersNovo HoldingsOmega Funds+1 more
Priothera is a clinical-stage biotech developing mocravimod (an S1P receptor modulator) for hematologic malignancies such as acute myeloid leukemia.
BiotechHealthtech
Florent Gros(Chief Executive Officer and Founder)Stephan Oehen(Chief Operating Officer and Founder)inBrice Suire(Chief Financial Officer and Founder)Nigel Clark(Chief Business Officer)Jens Hasskarl(Chief Medical Officer)
Co-investorsFountain Healthcare Partners4see Ventures
SynOx Therapeutics develops emactuzumab, a monoclonal antibody treatment for tenosynovial giant cell tumours (TGCT) and macrophage-mediated diseases.
BiotechHealthtechMedical Devices
Ray Barlow(Chief Executive Officer)in
Co-investorsBioqube VenturesForbionGimvMedicxiRed Tree Venture
CAR-Macrophage cellular therapeutics with initial oncology focus (NASDAQ: CARM).
BiotechPhiladelphia, US
Steven Kelly(Executive Officer, Director)in
BoardMargarita Chavez(Director)inEran Nadav(Director)Althea Stillman(Director)Jacob Gunterberg(Director)Regina Hodits(Director)in
Co-investorsAgent CapitalAju IB InvestmentAnzu PartnersGrazia Equity GmbHMRL Ventures FundSolasta Ventures+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.